Protagonist Therapeutics (PTGX) Leases (2019 - 2025)
Protagonist Therapeutics (PTGX) has disclosed Leases for 7 consecutive years, with $7.8 million as the latest value for Q4 2025.
- Quarterly Leases fell 16.86% to $7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2025, down 16.86% year-over-year, with the annual reading at $7.8 million for FY2025, 16.86% down from the prior year.
- Leases hit $7.8 million in Q4 2025 for Protagonist Therapeutics, down from $8.2 million in the prior quarter.
- In the past five years, Leases ranged from a high of $10.3 million in Q2 2024 to a low of $387000.0 in Q1 2024.
- Historically, Leases has averaged $5.2 million across 5 years, with a median of $4.6 million in 2021.
- Biggest five-year swings in Leases: plummeted 84.86% in 2024 and later skyrocketed 2225.58% in 2025.
- Year by year, Leases stood at $4.9 million in 2021, then crashed by 37.99% to $3.1 million in 2022, then plummeted by 68.83% to $954000.0 in 2023, then surged by 887.11% to $9.4 million in 2024, then dropped by 16.86% to $7.8 million in 2025.
- Business Quant data shows Leases for PTGX at $7.8 million in Q4 2025, $8.2 million in Q3 2025, and $8.6 million in Q2 2025.